We are excited to announce the newest addition to the International Accelerator portfolio, Docturnal, a groundbreaking MedTech startup! Founded by Rahul Pathri in 2016, Docturnal has rapidly scaled into a high-value company, leading innovative healthcare solutions.
About Docturnal
Docturnal is at the forefront of MedTech innovation, leveraging cutting-edge AI, machine learning, and acoustics to deliver next-generation screening and diagnostic solutions. Their flagship product, TimBre, revolutionizes respiratory and pulmonary screening by analyzing cough and voice as biomarkers to provide real-time results. Clinically validated for detecting conditions such as pulmonary tuberculosis, pneumonia, and COPD, TimBre is also expanding to include solutions for lung cancer and antimicrobial resistance (AMR).
What sets Docturnal apart is its unique ability to harness advanced technology to address critical healthcare challenges. By offering AI-driven, real-time diagnostics, the company is not only improving patient outcomes but also alleviating workforce shortages in healthcare, a sector that urgently needs such innovative solutions.
Meet the Founder
CEO, Rahul Pathri has built an impressive career in Silicon Valley before founding Docturnal. With experience in vairous companies like Affymetrix, Illumina, Amgen, Applabs, and Microsoft, Rahul has expertise in areas ranging from database development, data science, and software quality assurance to technical team and product management. This extensive background has equipped him with the vision and skills needed to lead a company that’s reshaping healthcare diagnostics.
At Docturnal, Rahul wears multiple hats, including that of a data scientist. He has developed sophisticated machine learning models that analyze patient clinical and cough signatures. Beyond product development, he has forged strategic partnerships with industry leaders like Molbio Diagnostics and GSK and initiated crucial regulatory processes with USFDA (SaMD) and CDSCO. His vision extends into the future of diagnostics, with plans to use voice biomarkers for early detection of neurological ailments.
As Docturnal embarks on this new chapter with International Accelerator, we are excited to support Rahul and his team in their mission to transform MedTech. We can’t wait to see how their journey unfolds and the impact they’ll make on global healthcare. Welcome to the International Accelerator family, Docturnal!
For more information about Docturnal, please visit www.docturnal.com.
About International Accelerator
International Accelerator is dedicated to empowering foreign-born entrepreneurs on their startup journey in the United States. Its 12-month program is designed to provide support and resources, allowing entrepreneurs to immerse themselves in the dynamic U.S. ecosystem. Since its inception, the International Accelerator has helped entrepreneurs from over 22 countries raise an estimated $145M, with a portfolio valuation of over $1B.
Comments